Total Payments
$589,973
2024 Payments
$3,668
Companies
20
Transactions
135
Payment Breakdown by Category
Research$580,258 (98.4%)
Travel$5,872 (1.0%)
Food & Beverage$2,643 (0.4%)
Consulting$1,100 (0.2%)
Education$99.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $580,258 | 49 | 98.4% |
| Travel and Lodging | $5,872 | 25 | 1.0% |
| Food and Beverage | $2,643 | 59 | 0.4% |
| Consulting Fee | $1,100 | 1 | 0.2% |
| Education | $99.99 | 1 | 0.0% |
Payments by Type
Research
$580,258
49 transactions
General
$9,715
86 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $559,722 | 15 | $0 (2019) |
| Eli Lilly and Company | $11,027 | 12 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $6,713 | 4 | $0 (2017) |
| UCB Biosciences Inc. | $2,561 | 20 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $1,985 | 4 | $0 (2017) |
| UCB SA | $1,616 | 13 | $0 (2018) |
| GlaxoSmithKline, LLC. | $1,337 | 13 | $0 (2018) |
| Incyte Corporation | $1,134 | 2 | $0 (2024) |
| Janssen Research & Development, LLC | $924.18 | 11 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $808.11 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,668 | 10 | Eli Lilly and Company ($2,042) |
| 2023 | $920.36 | 10 | Merck Sharp & Dohme LLC ($722.80) |
| 2021 | $489.41 | 2 | Eli Lilly and Company ($469.50) |
| 2020 | $5,161 | 22 | Eli Lilly and Company ($2,600) |
| 2019 | $399,060 | 12 | Bausch Health US, LLC ($398,050) |
| 2018 | $170,564 | 46 | Bausch Health US, LLC ($161,672) |
| 2017 | $10,110 | 33 | Valeant Pharmaceuticals North America LLC ($6,713) |
All Payment Transactions
135 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $49.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $34.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $24.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $24.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $249.66 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $126.58 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,893.00 | Research |
| Study: A STUDY OF LY3454738 IN THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | ||||||
| 08/22/2024 | Eli Lilly and Company | TALTZ (Drug) | — | In-kind items and services | $149.46 | Research |
| Study: EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) • Category: Immunology | ||||||
| 03/10/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Immunology | ||||||
| 01/24/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 11/01/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $51.75 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $25.94 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $291.44 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $186.45 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $143.29 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | Cash or cash equivalent | $13.31 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $10.62 | General |
| Category: IMMUNOLOGY | ||||||
| 03/18/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $33.51 | General |
| Category: Dermatology | ||||||
| 03/17/2023 | Arcutis Biotherapeutics, Inc. | — | Food and Beverage | In-kind items and services | $40.08 | General |
| 03/16/2023 | LEO Pharma Inc. | — | Food and Beverage | In-kind items and services | $123.97 | General |
| 08/06/2021 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: Immunology | ||||||
| 01/29/2021 | Eli Lilly and Company | — | — | In-kind items and services | $469.50 | Research |
| Study: PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS | ||||||
| 07/09/2020 | Eli Lilly and Company | — | — | In-kind items and services | $543.70 | Research |
| Study: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | ||||||
| 04/16/2020 | UCB Biosciences Inc. | — | Food and Beverage | Cash or cash equivalent | $25.46 | General |
| 04/16/2020 | UCB Biosciences Inc. | Bimekizumab | Food and Beverage | Cash or cash equivalent | $25.46 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B OPEN-LABEL STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS OF TOPICALLY APPLIED IDP-126 GEL IN COMPARISON WITH EPIDUO FORTE GEL IN SUBJECTS WITH MODERATE TO SEVERE ACNE VULGARIS UNDER MAXIMAL USE CONDITIONS | Bausch Health US, LLC | $392,100 | 3 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $125,405 | 5 |
| A Phase 1b Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison with EpiDuo Forte Gel 0.3 adapalene2.5 BPO in Subjects with Acne Vulgaris under Maximal Use Conditions | Bausch Health US, LLC | $34,750 | 4 |
| A PHASE 4, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-118 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Bausch Health US, LLC | $5,950 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Valeant Pharmaceuticals North America LLC | $4,363 | 2 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD | Eli Lilly and Company | $3,948 | 1 |
| PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $2,526 | 2 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $2,350 | 2 |
| An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $1,985 | 4 |
| A STUDY OF LY3454738 IN THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $1,893 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris | Bausch Health US, LLC | $1,517 | 2 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $929.09 | 1 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL-GROUP, | GlaxoSmithKline, LLC. | $922.21 | 12 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | Eli Lilly and Company | $543.70 | 1 |
| A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | ABBVIE INC. | $511.20 | 6 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $149.46 | 1 |
About Dr. Mark Lee, M.D
Dr. Mark Lee, M.D is a Dermatology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578532552.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Lee, M.D has received a total of $589,973 in payments from pharmaceutical and medical device companies, with $3,668 received in 2024. These payments were reported across 135 transactions from 20 companies. The most common payment nature is "" ($580,258).
Ad
Practice Information
- Specialty Dermatology
- Location San Antonio, TX
- Active Since 03/14/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1578532552
Products in Payments
- TALTZ (Drug) $6,096
- DUOBRII (Drug) $5,950
- DUPIXENT DUPILUMAB INJECTION (Biological) $1,985
- Bimekizumab $1,280
- RINVOQ (Biological) $511.20
- Tremfya (Drug) $149.29
- STELARA (Biological) $135.47
- Cimzia (Drug) $46.22
- OPZELURA (Drug) $33.51
- DUPIXENT (Biological) $19.91
- TREMFYA (Drug) $14.65
- REMICADE (Biological) $12.69
- Humira (Biological) $12.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in San Antonio
Dr. William Cragun, M.d, M.D
Dermatology — Payments: $1.9M
Dermatology $1.9M
Emily Becker, M.d, M.D
Dermatology — Payments: $937,773
Dermatology $937,773
Dr. Lindsey Finklea, M.d, M.D
Dermatology — Payments: $265,879
Dermatology $265,879
Steven Davis, Md, MD
Dermatology — Payments: $114,713
Dermatology $114,713
Stephen Miller, M.d. P.a, M.D. P.A
Dermatology — Payments: $89,896
Dermatology $89,896
Dr. Mobolaji Opeola, M.d, M.D
Dermatology — Payments: $66,660
Dermatology $66,660